the interaction of cytokines with peripheral nerves, circumventricular organs, and/or perivascular and meningial microglial cells (6) . Among the cytokines involved in this process are interleukin (IL)-1␣, IL-1␤, IL-6, IL-8, tumor necrosis factor-␣ (TNF-␣), and interferon -␥ (INF-␥) (13, 19) . These cytokines activate membrane receptors that signal through tyrosine kinases of the Janus kinase (JAK) family that are constitutively associated with their intracellular domains and become phosphorylated after receptor activation (10) . These activated JAKs phosphorylate intracellular tyrosine residues in these receptors, which then act as docking sites for signal transducers and activators of transcription (STATs) and other intracellular signaling proteins. These proteins are thought to initiate intracellular signaling pathways responsible for the production of mediators of fever such as PGs (19) .
Platelet-derived growth factor (PDGF) is a multifunctional protein that exerts particularly important actions in the CNS (27) . There are three isoforms of PDGF, denoted PDGF-AA, PDGF-AB, and PDGF-BB, which are homo-or heterodimers of related A and B polypeptide chains (5) . Like the cytokines, PDGF primarily relays information via tyrosine kinase-dependent pathways. It acts by binding to PDGF receptors (PDGFRs) with intrinsic tyrosine kinase activity that dimerize on ligand activation and become autophosphorylated on tyrosine residues. These residues act as binding sites for a group of proteins that contain Src homology 2 domains such as phospholipase C-␥, Src kinase, ras-GAP, and many others (5) . Like cytokine receptors, PDGFRs also activate multiple JAK family kinases and STAT proteins (29) .
PDGF and PDGFRs are widely expressed in both neurons and glial cells throughout the CNS (27) . PDGF-A and PDGF-B chains, as well as ␣PDGFR and ␤PDGFR, are expressed in cells of CNS regions that are important for control of body temperature, such as the hypothalamus, thalamus, cortex, hippocampus, and brain stem (15, 20, 24, 29, 31) . However, the functions of PDGF in these and other regions of the adult mammalian CNS are only partially understood. In the hippocampus, PDGF was shown to produce a longlasting modulatory effect on the function of GABA a and N-methyl-D-aspartate receptors, which are two of the most important inhibitory and excitatory ligand-gated ion channels in this region and many other regions of the CNS, respectively (26, 28) . Intracerebroventricular infusion of PDGF was reported to modulate specific components of the feeding response in mice (18, 21) . Moreover, PDGF levels are elevated in several CNS diseases associated with fever, such as trauma, stroke, meningitis, cerebral abscesses, glial and meningeal cysts, and neoplasia (11, 14) . Thus PDGF appears to be important for the function of the CNS, not only under physiological conditions, but also during pathophysiological states.
We recently reported (17) that microinjections of PDGF-BB (10-50 ng) into the lateral ventricle produced a febrile response in rats. We also showed (17) that this febrile response was blocked by pretreatment with Win 41662, a potent blocker of the intrinsic tyrosine kinase activity of PDGFR. In this study, we present a more detailed characterization of the PDGF-BB-induced febrile responses in rats. We evaluated the effect of microinjections of three different concentrations of PDGF-BB into the third ventricle. We determined the effect of Win 41662 on bacterial lipopolysaccharide (LPS)-and cytokine-induced changes in body temperature. We also studied the effects of indomethacin and dexamethasone on the PDGF-BB-induced febrile response.
MATERIALS AND METHODS
Male Wistar rats (170-200 g) were used. All animals were housed in individual cages at an ambient temperature of 23-25°C with standard laboratory diet and tap water ad libitum. Lighting was on a 12:12-h light-dark cycle, beginning at 6 AM. One week before the experiments, rats were anesthetized with pentobarbitone (45 mg/kg ip) and stereotaxically implanted with a stainless steel guide cannula (0.8 mm OD ϫ 15 mm length). The cannula was implanted into the right lateral ventricle [coordinates in relation to the bregma: area postrema 0.8 mm, (L) 1.5 mm, and (V) 4 mm] or into the third ventricle (coordinates in relation to the bregma: area postrema Ϫ0.8 mm, L 1.5 mm, and V 12.5) according to Paxinos and Watson (16) . Each guide cannula was fixed to the skull by an acrylic dental cement attached to two selftrapping stainless steel screws inserted into the frontal bones of the animals. At the end of each experiment, the position of the cannula was confirmed histologically.
Colonic temperature was measured with a telethermometer (Yellow Spring Instruments) in animals that were conscious and gently restrained only at the moment of the measurement. Plastic-coated thermocouples were inserted 5 cm beyond the anal sphincter. All animals were trained to accept handling and colonic temperature measurements the day before the experiments. All temperature measurements were performed at 30-min intervals. Baseline temperature measurements were obtained 2 h before drug application. Basal colonic temperature was the average of four measurements made before any treatment. Effects of drugs on temperature were measured for 6-7 h. All experiments were performed at the thermoneutral zone for rats (28 Ϯ 1°C).
All drugs were dissolved in pyrogen-free saline (0.9% NaCl) and microinjected in a 2 µl vol over a 30-s period, using a stainless steel needle (70 mm OD). Recombinant human (rh) PDGF-BB and Win 41662 were a gift from Amgen (Boulder, CO) and Sanofi Laboratories (Toulouse, France), respectively. PDGF-BB and BSA (0.01% ) solutions were determined to be endotoxin-free by means of the limulus amoebocyte lysate (LAL) (QCL-1000 quantitative chromogenic LAL, BioWittaker) (8) . PDGF-BB samples were sonicated and placed in plastic containers to minimize loss of material. These samples contained final BSA concentrations of 0.001%. Control experiments demonstrated that these concentrations of BSA did not change body temperature. BSA, LPS (Escherichia coli, 0111: B4), rhTNF-␣, rhIL-1␤, and rhIL-6 were from Sigma Chemical (St. Louis, MO). Indomethacin, supplied as a base by Merck Sharp and Dohme, was dissolved in pyrogen-free 0.2 M Tris · HCl buffer, pH 8.2, immediately before intraperitoneal injection. Dexamethasone (Decadronal; Prodrome) was dissolved in pyrogen-free saline immediately before subcutaneous injection.
All values are means Ϯ SE. Statistical differences were determined by one-way ANOVA followed by Duncan's post hoc test or by two way ANOVA using statistical software from SPSS (Chicago, IL). P Յ 0.05 was considered statistically significant. Area under the curve over the 6-h monitoring period (i.e., fever index; expressed in°C · h) and linear regression analysis were performed with Fig.P software (Biosoft, Cambridge, UK). For linear regression analysis, we used the equation y ϭ 1.63x ϩ 0.92 (for intracerebroventricular injection) and y ϭ 1.57x ϩ 1.14 (for injection into the third ventricle), where y is the fever index and x is the log of the PDGF-BB dose.
RESULTS
Microinjection of PDGF-BB into the third ventricle induced a dose-dependent increase in colonic temperature (Fig. 1A ). Injection of 10 and 100 ng of PDGF-BB induced a statistically significant increase in colonic temperature that peaked 3-4 h after injection (P Ͻ 0.0001, one-way ANOVA). The peak changes in colonic temperature induced by 1, 10, and 100 ng of PDGF-BB were 0.3 Ϯ 0.09, 0.6 Ϯ 0.2, and 1.0 Ϯ 0.2°C, respectively. The increase in colonic temperature remained stable until the end of the experiment (6 h after injection). The fever indexes (area under the curve over the 6-h monitoring period) were 1.1 Ϯ 0.3, 2.7 Ϯ 0.7, and 4.3 Ϯ 0.8°C · h in animals injected with 1, 10, and 100 ng of PDGF-BB, respectively (Fig. 1B) . The effect of PDGF-BB injection on the fever index was linear (r ϭ 0.99) with respect to the PDGF-BB doses used.
Microinjection of PDGF-BB into the lateral ventricle also induced a statistically significant increase (P Ͻ 0.05, one-way ANOVA) in colonic temperature (data not shown). This increase in colonic temperature peaked 3-4 h after injection. The peak changes in colonic temperature induced by 1, 10, and 100 ng of PDGF-BB were 0.2 Ϯ 0.1, 0.7 Ϯ 0.1, and 1.0 Ϯ 0.1°C, respectively. The increase in colonic temperature remained stable until the end of the experiment (6 h after injection). Fever indexes were 0.8 Ϯ 0.4, 2.8 Ϯ 0.3, and 4.1 Ϯ 0.5°C · h in animals injected with 1, 10, and 100 ng of PDGF-BB, respectively. The effect of PDGF-BB injection on the fever index was also linear (r ϭ 0.99) with respect to the PDGF-BB doses used. These findings are in agreement with our previously published results (17) .
We next investigated the effect of Win 41662, a potent inhibitor of the intrinsic tyrosine kinase activity of PDGFRs (22), on LPS-induced fever. Win 41662 was reported to competitively inhibit PDGFR tyrosine kinase activity in vitro with a Michaelis inhibitor constant of 15 Ϯ 5 nM and to inhibit PDGF-BB-induced Ca 2ϩ mobilization and proliferation in intact human vascular smooth muscle cells with an IC 50 of 0.43 and 2.3 µM, respectively. Previously, we showed (17) that treatment with Win 41662 significantly reduced the increase of colonic temperature induced by microinjection of PDGF-BB into the lateral ventricle. In the present study, we show that this antagonist also inhibits LPS-induced fever. LPS (10 µg/kg ip) induced an increase in colonic temperature of 0.7 Ϯ 0.1°C 3 h postinjection (Fig. 2) . In animals pretreated with Win 41662 (4 µM into the lateral ventricle, 15 min before injection), LPS only induced a change of 0.3 Ϯ 0.1°C 3 h postinjection. Statistical analysis revealed that Win 41662 significantly decreased the LPS-induced change in colonic temperature (two-way ANOVA, P Ͻ 0.0001). It should be noted that intracerebroventricular injection of Win 41662 alone did not induce a significant effect on basal colonic temperature (Fig. 2) . (Figs. 3, 4, and 5) .
Finally, we investigated the effect of indomethacin and dexamethasone on the increase in colonic temperature induced by microinjection of PDGF-BB (10 ng) into the lateral ventricle. Indomethacin (2 mg/kg ip, 30 min before PDGF-BB injection) markedly reduced the PDGF-BB-induced increase in colonic temperature (Fig.  6) . Microinjection of PDGF-BB induced an increase in colonic temperature of 1.2 Ϯ 0.1°C 4 h postinjection, whereas in the group pretreated with indomethacin it only induced a change of 0.4 Ϯ 0.1°C 4 h postinjection. Dexamethasone (1 mg/kg sc, 35 min before PDGF-BB injection) also blocked the PDGF-BB-induced increase in colonic temperature (Fig. 7) . Microinjection of PDGF-BB induced an increase in colonic temperature of 1.0 Ϯ 0.2°C 4 h postinjection, whereas in the group pretreated with dexamethasone it only induced a change of 0.3 Ϯ 0.1°C 3 h postinjection. Statistical analysis revealed that both indomethacin and dexamethasone significantly reduced the increase in colonic temperature induced by PDGF-BB (two-way ANOVA, P Ͻ 0.001). It should be noted that injection of indomethacin or dexamethasone alone did not significantly affect basal colonic temperature (Figs. 6-7) .
DISCUSSION
The results of the present study suggest that PDGF-BB is a novel endogenous pyrogen in the rat CNS. PDGF-BB appears to fulfill some of the criteria that a substance must meet to be considered an endogenous mediator of fever (13) . One criterion is that application of the putative mediator of fever at the hypothetical site of action results in a rise in body temperature and that the effect is dose dependent. Present results show that this occurs after intracerebroventricular injection of exogenous PDGF-BB. We observed dose-dependent changes in body temperature after injection of PDGF-BB into the lateral or third ventricle in amounts ranging from 10 to 100 ng per animal. Assuming that the average cerebrospinal fluid (CSF) volume in an adult rat is ϳ250 µl (1), then the concentrations of PDGF-BB that are required to achieve this effect appear to fall within physiologically relevant limits. PDGF concentrations in whole blood were reported to be ϳ17 and 3 ng/ml in humans and baboons, respectively (2). Unfortunately, normal values for PDGF-BB levels in the CSF for any animal species have yet to be reported. In a recent study (14) , however, it was shown that PDGF levels can reach values ranging from 10 to 200 ng/ml in the CSF of patients with neoplastic and nonneoplastic brain lesions, including CNS infections. Thus the PDGF-BB levels achieved during our experiments can be probably found in the CSF at least during some pathophysiological conditions of the CNS.
Another criterion for a substance to be considered an endogenous pyrogen is that its effect be prevented by blockers of its pathway of action (13) . Indeed, we have shown (17) that Win 41662 blocks the PDGF-BB-and LPS-induced febrile responses in rats. Win 41662 is a novel biarylhydrazone that appears to be competitive with respect to substrate (Mn 2ϩ -ATP) and is specific to PDGFRs in comparison to other tyrosine kinase receptors (epidermal growth factor receptor, p561ck, erbB2), cAMP-dependent protein kinase or protein kinase C (22) . Importantly, the same dose of Win 41662 that inhibited fever induced by PDGF-BB and LPS did not change the response induced by TNF-␣, IL-1␤, and IL-6, which also activate receptors that signal through tyrosine kinases (10) . Although it cannot be completely ruled out that the antipyretic effect of Win 41662 may be due to nonspecific effects, these results suggest that it blocks the PDGF-BB-and LPS-induced febrile responses by specifically preventing activation of the PDGFR intrinsic tyrosine kinase activity. These results can also be interpreted to indicate that the role of PDGF-BB in the febrile response induced by an exogenous pyrogen like LPS precedes the involvement of the mentioned cytokines. However, it must be kept in mind that PDGF-BB and the cytokines could also act concomitantly to induce the elevation in rat body temperature. Evidence is beginning to emerge indicating that PDGF-BB and cytokines can induce expression of each other. PDGF-BB has been shown to induce IL-6 expression in osteoblasts (7), whereas cytokines (TNF-␣, TGF-␤1, and IL-1␤) have been shown to induce PDGF expression in human astrocytes (23) . Thus establishing the role of PDGF-BB in the sequence of events that mediate a complex biological response such as the generation of fever is a challenging question for future research.
Additional criteria for a substance to be considered an endogenous mediator of fever involve the demonstration that the putative mediator is produced during a naturally occurring fever and that there is a relationship between its production and the magnitude of fever. Although our study does not directly demonstrate that PDGF-BB meets these criteria, our finding that Win 41662 blocks LPS-induced fever suggests that this growth factor is produced in response to this bacterially derived pyrogen. As mentioned before, PDGF-BB and PDGFRs are endogenously expressed in neuronal and glial cells of CNS regions closely involved in the generation of fever, such as the hypothalamus (15, 20, 24, 29, 31, 32 ). Thus we postulate that endogenous PDGF-BB may be released from neuronal and/or glial cells in response to intraperitoneal injection of LPS and that PDGFRs become activated in the process, contributing to the generation of fever. However, definitive proof that PDGF-BB meets these criteria will require, for example, determining CSF levels of this growth factor in response to pyrogenic stimuli. It should also be noted that we previously reported (17) that boiled PDGF-BB did not induce fever in rats. It is unclear why boiling produced this effect since PDGF-BB is a thermostable protein (for review, see Ref. 27) . This effect of boiling may be due to partial denaturation of a critical domain of PDGF-BB required for fever induction or to PDGF-BB depletion due to binding to tube walls. This uncertainty must be kept in mind when interpreting the results of the present study.
Our finding that indomethacin markedly inhibited the PDGF-BB-induced increase in colonic temperature suggest that cyclooxygenase (COX)-dependent pathways may be involved in this process. Inducible enzymes, such as phospholipase A 2 (PLA 2 ), COX2, and inducible nitric oxide synthase, may also be involved, as previous treatment of rats with dexamethasone significantly inhibited PDGF-induced increases in colonic temperature. Little is known about the effects of PDGF-BB on the activity of brain PLA 2 and other enzymes such as COX1 and COX2 or about its effects on the synthesis and release of arachidonic acid and PGs. However, it is well established that this growth factor can activate arachidonic acid-and PG-related biochemical pathways in nonneuronal cells. PDGF-BB was shown to induce arachidonic acid and PGE 2 synthesis and release and to transcriptionally regulate gene expression of COX2 in NIH 3T3 fibroblasts (4, 12, 30) . PDGF-BB was also shown to stimulate the rapid release of arachidonic acid and PGE 2 in human arterial smooth muscle cells by a mechanism involving Ca 2ϩ and mitogen-activated protein kinase-dependent activation of cytosolic PLA 2 (9) . Moreover, activation of cytosolic PLA 2 by PDGF-BB was shown to be essential for COX2-dependent PGE 2 synthesis in mouse osteoblasts cultured with IL-1 (3). Thus it is possible that PDGF-BB induces fever via similar mechanisms in certain neuronal or glial cell populations.
Perspectives
This study presents evidence that PDGF-BB may be a novel mediator of the febrile response in the CNS of rats. The precise mechanism of action of PDGF-BB and the CNS region(s) involved in this process, including the hypothalamus, are presently under investigation. The hypothalamus is recognized as one of the most important regions for the control, not only of body temperature, but also of food intake and autonomic outflow (19) . Interestingly, intracerebroventricular injection of PDGF was shown to modulate feeding responses in rats (18, 21) and PDGF-BB levels were shown to increase in the rat CSF after feeding (21) . Therefore, PDGF-BB could be an important mediator of hypothalamic regulatory functions of body temperature and food intake. Important tasks for future research on the role of PDGF-BB in hypothalamic function include the determination of which specific hypothalamic regions express PDGFs and PDGFRs and the details of the intracellular signaling cascades activated and/or modulated by this growth factor in this CNS region. These studies should also be extended to parts of the brain that may be involved in thermoregulation, such as the hippocampus, cortex, and thalamus.
